Table 6

Univariate and multivariable analysis of PFS and OS in all patients (N = 186)
Risk Factor Univariate analysis Multivariable analysisa
PFS OS PFS OS
HR 95 % CI P HR 95 % CI P HR 95 % CI P HR 95 % CI P
Prior capecitabine vs. no prior capecitabine 1.50 1.12-2.02 0.0072 1.33 0.97-1.83 0.0790 1.22 0.89-1.67 0.2140 0.73 0.48-1.10 0.1351
Hormone receptor positive vs. hormone receptor negative 0.78 0.57-1.06 0.1064 0.80 0.57-1.11 0.1741
Best systemic response SD, PD vs. CR, PR 2.54 1.85-3.48 <0.0001 1.88 1.33-2.64 0.0003 2.60 1.87-3.63 <0.0001 1.31 0.86-1.99 0.2064
Median prior trastuzumab duration, wks ≥24.1 vs. <24.1 0.68 0.50-0.91 0.0108 0.57 0.41-0.78 0.0006 0.66 0.48-0.89 0.0074 0.68 0.48-0.96 0.0271
Age ≥50 vs. <50 0.89 0.66-1.20 0.4418 0.84 0.61-1.15 0.2726
No. of metastasis ≥3 vs. <3 1.16 0.86-1.16 0.3427 1.64 1.18-2.28 0.0034 1.78 1.23-2.58 0.0023
No. of prior chemotherapy regimens >3 vs. ≤3 1.17 0.86-1.58 0.3214 1.58 1.14-2.19 0.0067 1.64 1.08-2.47 0.0194
Pattern of metastasis Visceral only vs. other 1.58 1.17-2.15 0.0031 0.98 0.70-1.36 0.8928 1.61 1.18-2.21 0.0031
Median TTP, wks ≥20.0 vs. <20.0 0.36 0.26-0.50 <0.0001 0.37 0.25-0.56 <0.0001
Brain metastasis vs. no brain metastasis 0.98 0.71-1.35 0.8979 1.23 0.88-1.74 0.2310

a Risk factors were determined using univariate Cox’s proportional hazards regression (α <0.10).

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; TTP, time to disease progression.

HR, hazard ratio; CI, confidence interval.

Ro et al.

Ro et al. BMC Cancer 2012 12:322   doi:10.1186/1471-2407-12-322

Open Data